Pasithea Therapeutics Reports Improved Q1 Net Loss, Strong Cash Position, and Increased R&D Spending
KTTA has more than doubled off its 52-week low of $0.281.
Summary
Pasithea Therapeutics reported an improved Q1 net loss and a robust $50.4 million cash balance, providing a solid runway for its significantly increased R&D efforts, crucial for a clinical-stage biotech facing Nasdaq compliance issues.
Key Events · Earnings and Guidance · KTTA
-
Improved Net Loss
Net loss decreased to $(2.87) million in Q1 2026 from $(3.56) million in Q1 2025.
-
Strong Cash Position
The company holds $50.4 million in cash and equivalents as of March 31, 2026, providing over 12 months of liquidity.
-
Increased R&D Investment
Research and development expenses rose 70.1% to $2.94 million, reflecting continued pipeline advancement.
-
Warrant Reclassification
$2.29 million in December 2025 Placement Agent Warrants were reclassified from liability to equity following an increase in authorized shares.
Analysis · KTTA · Life Sciences
Pasithea Therapeutics, a clinical-stage biotech, reported an improved net loss for Q1 2026 and maintains a substantial cash balance of $50.4 million, which management believes is sufficient for over 12 months of operations. This strong liquidity is critical, especially following a recent Nasdaq deficiency notice. The company also significantly increased its R&D spending by 70.1%, signaling continued investment in its pipeline, including the PAS-004 program which recently received FDA Fast Track and Rare Pediatric Disease designations.
At the time of this filing, KTTA was trading at $0.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.5M. The 52-week trading range was $0.28 to $2.06. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.